Literature DB >> 31682153

DSM-5 substance use disorder symptom clusters and HIV antiretroviral therapy (ART) adherence.

Margaret M Paschen-Wolff1, Aimee N C Campbell1, Susan Tross2, Tse-Hwei Choo3, Martina Pavlicova4, Don Des Jarlais5.   

Abstract

This study examines self-reported 30-day antiretroviral therapy (ART) adherence among 101 people living with HIV and substance use disorders (SUD) in New York City in terms of Diagnostic and Statistical Manual - 5th Edition (DSM-5) SUD symptom clusters: impaired control, social impairment, risky use and pharmacological criteria. Overall, 60.4% met DSM-5 criteria for stimulant, 55.5% for alcohol, 34.7% for cannabis and 25.7% for opioid SUD. Of the 76 participants with a current ART prescription, 75.3% reported at least 90% 30-day adherence. Participants with vs. without alcohol SUD were significantly less likely to report ART adherence (64.3% vs. 88.2%, p = .017). Endorsement of social impairment significantly differed among adherent vs. non-adherent participants with alcohol SUDs (74.1% vs. 100%, p = .038) and with opioid SUDs (94.1% vs. 50.0%, p = .040). Understanding specific SUD symptom clusters may assist providers and patients in developing strategies to improve ART adherence.

Entities:  

Keywords:  Antiretroviral therapy; DSM-5; HIV/AIDS; medication adherence; substance use disorders

Mesh:

Year:  2019        PMID: 31682153      PMCID: PMC7103534          DOI: 10.1080/09540121.2019.1686600

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  24 in total

1.  Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States.

Authors:  Bryan Hartzler; Julia C Dombrowski; Heidi M Crane; Joseph J Eron; Elvin H Geng; W Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan
Journal:  AIDS Behav       Date:  2017-04

2.  Drug use and medication adherence among HIV-1 infected individuals.

Authors:  Charles H Hinkin; Terry R Barclay; Steven A Castellon; Andrew J Levine; Ramani S Durvasula; Sarah D Marion; Hector F Myers; Douglas Longshore
Journal:  AIDS Behav       Date:  2007-03

3.  Attitudes and Training Needs of New England HIV Care and Addiction Treatment Providers: Opportunities for Better Integration of HIV and Alcohol Treatment Services.

Authors:  Brian T Montague; Christopher W Kahler; Suzanne M Colby; R Kathryn McHugh; Daniel Squires; Brianne Fitzgerald; Don Operario; Donna Gallagher; Peter M Monti; Kenneth H Mayer
Journal:  Addict Disord Their Treat       Date:  2015-03

Review 4.  Alcohol use and antiretroviral adherence: review and meta-analysis.

Authors:  Christian S Hendershot; Susan A Stoner; David W Pantalone; Jane M Simoni
Journal:  J Acquir Immune Defic Syndr       Date:  2009-10-01       Impact factor: 3.731

Review 5.  Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals.

Authors:  Gregory M Lucas
Journal:  Life Sci       Date:  2010-10-01       Impact factor: 5.037

6.  Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  Lisa R Metsch; Christine Bell; Margaret Pereyra; Gabriel Cardenas; Tanisha Sullivan; Allan Rodriguez; Lauren Gooden; Nayla Khoury; Tamy Kuper; Toye Brewer; Carlos del Rio
Journal:  Am J Public Health       Date:  2009-04-16       Impact factor: 9.308

7.  Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders.

Authors:  Claude Ann Mellins; Jennifer F Havens; Cheryl McDonnell; Carolyn Lichtenstein; Karina Uldall; Margaret Chesney; E Karina Santamaria; James Bell
Journal:  AIDS Care       Date:  2009-02

8.  Illicit drug use and HIV treatment outcomes in a US cohort.

Authors:  Joseph Cofrancesco; Rebecca Scherzer; Phyllis C Tien; Cynthia L Gibert; Heather Southwell; Stephen Sidney; Adrian Dobs; Carl Grunfeld
Journal:  AIDS       Date:  2008-01-30       Impact factor: 4.177

Review 9.  Mental, neurological, and substance use disorders in people living with HIV/AIDS in low- and middle-income countries.

Authors:  Dixon Chibanda; Laura Benjamin; Helen A Weiss; Melanie Abas
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

10.  Antiretroviral medication treatment for all HIV-infected individuals: a protocol using innovative multilevel methodologies to evaluate New York City's universal ART policy among problem substance users.

Authors:  Aimee N C Campbell; Don Des Jarlais; Cooper Hannah; Sarah Braunstein; Susan Tross; Laura Kersanske; Christine Borges; Martina Pavlicova; Kevin Jefferson; Howard Newville; Laurel Weaver; Margaret Wolff
Journal:  BMC Health Serv Res       Date:  2016-08-02       Impact factor: 2.655

View more
  4 in total

1.  Exploring the Association Between Social Support and Hazardous Alcohol Use Among Persons Living with HIV in South Western Uganda.

Authors:  Christine Ngabirano; Robin Fatch; Winnie R Muyindike; Nneka I Emenyonu; Julian Adong; Sheri D Weiser; Jeffrey H Samet; Debbie M Cheng; Judith A Hahn
Journal:  AIDS Behav       Date:  2022-01-18

2.  Using a Syndemics Framework to Understand How Substance Use Contributes to Morbidity and Mortality among People Living with HIV in Africa: A Call to Action.

Authors:  Emmanuel Peprah; Bronwyn Myers; Andre-Pascal Kengne; Nasheeta Peer; Omar El-Shahawy; Temitope Ojo; Barbara Mukasa; Oliver Ezechi; Juliet Iwelunmor; Nessa Ryan; Fatoumata Sakho; John Patena; Joyce Gyamfi
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

3.  mHealth Intervention to Improve Treatment Outcomes Among People With HIV Who Use Cocaine: Protocol for a Pilot Randomized Controlled Trial.

Authors:  Yerina S Ranjit; Archana Krishnan; Debarchana Ghosh; Claire Cravero; Xin Zhou; Frederick L Altice
Journal:  JMIR Res Protoc       Date:  2022-03-07

Review 4.  Confound, Cause, or Cure: The Effect of Cannabinoids on HIV-Associated Neurological Sequelae.

Authors:  Alexander Starr; Kelly L Jordan-Sciutto; Eugene Mironets
Journal:  Viruses       Date:  2021-06-26       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.